Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE...
Rheumatology
Oral tacrolimus noninferior to intravenous cyclophosphamide for lupus nephritis
1. Oral tacrolimus was noninferior to intravenous cyclophosphamide for lupus nephritis disease measures with lower toxicity. Evidence Rating Level: 1...
Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia
1. Rilzabrutinib was active and 400mg twice daily was identified as the dose for further testing with low-level toxic effects....
Prenatal exposure to maternal autoimmune diseases associated with increased risks of mental disorders in offspring
1. In utero exposure to any maternal autoimmune disease was associated with increased risks of overall and type-specific mental disorders...
Initiation of targeted disease-modifying antirheumatic drugs in patients with rheumatoid arthritis not associated with reduced risk of Alzheimer disease and related dementia
1. There were no differences in the risk of Alzheimer disease and related dementia in patients with rheumatoid arthritis treated...
Donidalorsen reduces attacks in patients with C1 inhibitor deficiency
1. Patients with hereditary angioedema receiving donidalorsen showed reduced rates of angioedema attacks compared to patients receiving placebo treatment. 2....
Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus
1. More patients with systemic lupus erythematosus (SLE) who received high doses of iberdomide achieved SRI-4 response compared to placebo...
Systematic review of Kawasaki disease shows excellent long-term survival
1. In a systematic review of 74 studies reporting Kawasaki disease (KD) outcomes over years of follow-up, overall mortality estimates...
Allopurinol does not increased mortality in gout and chronic kidney disease patients
1. In patients with gout and chronic kidney disease, the initiation of allopurinol was not associated with increased mortality. 2....
Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis
1. Patients with rheumatoid arthritis (RA) treated with tofacitinib showed a higher risk of developing major adverse cardiovascular events and...